Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Victor S Lin"'
Autor:
Victor S. Lin, Emily Sun, Serine Yau, Chathuri Abeyakoon, Georgia Seamer, Simran Bhopal, Harriet Tucker, Carolyn Doree, Susan J. Brunskill, Zoe K. McQuilten, Simon J. Stanworth, Erica M. Wood, Laura Green
Publikováno v:
Critical Care, Vol 27, Iss 1, Pp 1-12 (2023)
Abstract Background Definitions for massive transfusion (MT) vary widely between studies, contributing to challenges in interpretation of research findings and practice evaluation. In this first systematic review, we aimed to identify all MT definiti
Externí odkaz:
https://doaj.org/article/fd0237ddff644828852cb0c7234d1975
Autor:
Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil A. Came, Piers Blombery, David A. Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 165-173 (2020)
Abstract: The highly selective BCL2 inhibitor venetoclax achieves deep responses in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), including undetectable minimal residual disease (uMRD). We retrospectively reviewed 62
Externí odkaz:
https://doaj.org/article/5f39def7fd624a1e988b87b4b9f93212
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ee45fc98c075ecc6b0f0517acd16237
https://doi.org/10.1182/blood.2021012775
https://doi.org/10.1182/blood.2021012775
Autor:
Bryone J. Kuss, David Westerman, Piers Blombery, Sasanka M. Handunnetti, John F. Seymour, Constantine S. Tam, David C. S. Huang, Victor S Lin, Andrew W. Roberts, Thomas E Lew, Mary Ann Anderson, Edward Robert Scheffer Cliff, Ella R. Thompson
Publikováno v:
Blood Advances. 5:4054-4058
Covalent Bruton tyrosine kinase inhibitors (BTKi’s) and the B-cell lymphoma 2 (BCL2) inhibitor venetoclax have significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL), especially those with biologically adverse disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3e67aa01aae1c4850d6229c6d0e623c
https://doi.org/10.1182/bloodadvances.2021005083
https://doi.org/10.1182/bloodadvances.2021005083
Autor:
Elena Savva, Ivan Macciocca, Tiong Yang Tan, Victor S Lin, Ivone U.S. Leong, Mark J. Caulfield, Richard H. Scott, Ana Lisa Taylor Tavares, Crystle Lee, Kevin Savage, Kathryn N. North, Olivia Niblock, Christopher Boustred, Sarah Leigh, Arina Puzriakova, Ellen M. McDonagh, Alison Yeung, William Bellamy, Catherine E. Snow, Ellen R.A. Thomas, Antonio Rueda-Martin, Paul De Fazio, Bryony A. Thompson, Louise C. Daugherty, Helen K. Brittain, Eleanor Williams, Chirag Patel, Oliver Hofmann, Ain Roesley, Zornitza Stark, Jane Deller, Zandra C. Deans, Susan M. White, Rebecca E. Foulger, Lilian Downie, Sue Hill, Augusto Rendon, Sebastian Lunke, Meriel McEntagart, Oleg Gerasimenko, Lavinia Gordon, Roman Valls
Publikováno v:
Am J Hum Genet
Clinical validity assessments of gene-disease associations underpin analysis and reporting in diagnostic genomics, and yet wide variability exists in practice, particularly in use of these assessments for virtual gene panel design and maintenance. Ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0a7bb1d7c13503703eaacf84893bd36
https://doi.org/10.1016/j.ajhg.2021.06.020
https://doi.org/10.1016/j.ajhg.2021.06.020
Autor:
Sasanka M. Handunnetti, Constantine S. Tam, John F. Seymour, Meaghan Wall, David Westerman, Andrew W. Roberts, Thomas E Lew, Neil Came, Mary Ann Anderson, Victor S Lin, Piers Blombery
Publikováno v:
Blood Advances. 4:165-173
The highly selective BCL2 inhibitor venetoclax achieves deep responses in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), including undetectable minimal residual disease (uMRD). We retrospectively reviewed 62 patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c2075fc4120b64a3ac25c057ff76ed7
https://doi.org/10.1182/bloodadvances.2019000864
https://doi.org/10.1182/bloodadvances.2019000864
Publikováno v:
Military medicine.
Introduction Based on defining criteria, hypertension (HTN) affects 31% to 46% of the adult U.S. population and almost 20% of service members. Resistant HTN (rHTN) consumes significant resources, carries substantial morbidity and mortality risk and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::824d474d6529ab7b3ede9cc39afc2df9
https://pubmed.ncbi.nlm.nih.gov/33007059
https://pubmed.ncbi.nlm.nih.gov/33007059
Autor:
Thomas E Lew, Mary Ann Anderson, Sasanka M. Handunnetti, Victor S Lin, Andrew W. Roberts, Constantine S. Tam, John F Seymour, Tamia Nguyen, Bryone J. Kuss, David Westerman, Piers Blombery
Publikováno v:
Blood
Highly active BTK inhibitors (BTKis) and the BCL2 inhibitor venetoclax have transformed the therapeutic landscape for chronic lymphocytic leukemia (CLL). Results of prospective clinical trials demonstrate the efficacy of venetoclax to salvage patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98b5eb73cd81a68c0944b29fd9bcd37a
https://pubmed.ncbi.nlm.nih.gov/32556131
https://pubmed.ncbi.nlm.nih.gov/32556131
Publikováno v:
Cancers
Cancers, Vol 12, Iss 3353, p 3353 (2020)
Cancers, Vol 12, Iss 3353, p 3353 (2020)
Simple Summary B-cell malignancies, including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and plasma cell dyscrasias, are significant contributors to cancer morbidity and mortality worldwide. The pathogenesis of many B-cell malign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e21cad2dc5852c07fb4ad3199a18b2
https://doi.org/10.3390/cancers12113353
https://doi.org/10.3390/cancers12113353
Autor:
Neil Came, Sasanka M. Handunnetti, Surender Juneja, David Westerman, John F. Seymour, Victor S Lin, Thomas E Lew, Andrew W. Roberts, Dennis A. Carney, Max Wolf, Constantine S. Tam, Mary-Ann Anderson
Publikováno v:
Hematological Oncology. 37:108-109
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c2ed414aa7d6556f5b323a59495df2b
https://doi.org/10.1002/hon.70_2629
https://doi.org/10.1002/hon.70_2629